Metformin and Systemic Metabolism.
Level 5 - mechanism / opinion, no new human data
Narrative review describing molecular mechanisms and physiological pathways without original human trial data.
PubMed 32994049 · doi:10.1016/j.tips.2020.09.001
What was done
This is a narrative review outlining the current understanding of how metformin affects systemic metabolism, detailing its tissue-specific molecular mechanisms across the liver, intestine, gut microbiome, and adipose tissue.
What was found
Metformin reaches concentrations up to 300 times higher in the intestine than in systemic circulation. In intestinal epithelial cells and the microbiome, it alters nutrient metabolism to increase lactate production. Hepatocytes consume this lactate for gluconeogenesis at an energetic cost, establishing a futile intestine-liver metabolic cycle. Metformin also lowers circulating lipopolysaccharide (LPS) levels, dampens LPS-induced low-grade inflammation, increases oxidative phosphorylation in the liver and adipose tissue, and improves peripheral insulin sensitivity and glucose utilization. The abstract provides no primary clinical metrics or statistical effect sizes.
Why it matters
It highlights that metformin's therapeutic effects extend beyond simple suppression of hepatic gluconeogenesis to include gut-mediated energy expenditure and reduction of systemic endotoxemia-driven inflammation.
Limits
As a narrative review, it does not provide systematic search methods, sample sizes, patient demographics, or quantitative clinical effect estimates.
Cited by
- context Metformin improves insulin sensitivity to clear glucose from the bloodstream into cells for energy.